FDA finds Chinese lab copied or falsified data, endangering patients
The FDA said the findings raise doubts about the reliability and viability of premarket submissions based on the company’s data.
The FDA said the findings raise doubts about the reliability and viability of premarket submissions based on the company’s data.
